NeuroMetrix, Inc. (NURO)
- Previous Close
4.1200 - Open
4.3200 - Bid --
- Ask --
- Day's Range
4.2799 - 4.3800 - 52 Week Range
2.6600 - 5.6000 - Volume
4,534 - Avg. Volume
19,593 - Market Cap (intraday)
8.789M - Beta (5Y Monthly) 2.29
- PE Ratio (TTM)
-- - EPS (TTM)
-5.4400 - Earnings Date Oct 24, 2024 - Oct 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Mar 28, 2007
- 1y Target Est
--
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
www.neurometrix.comRecent News: NURO
View MorePerformance Overview: NURO
Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NURO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NURO
View MoreValuation Measures
Market Cap
8.66M
Enterprise Value
-7.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.47
Price/Book (mrq)
0.50
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-181.03%
Return on Assets (ttm)
-24.94%
Return on Equity (ttm)
-40.99%
Revenue (ttm)
4.38M
Net Income Avi to Common (ttm)
-7.94M
Diluted EPS (ttm)
-5.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
16.43M
Total Debt/Equity (mrq)
1.02%
Levered Free Cash Flow (ttm)
-3.5M